These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 10678926)

  • 1. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.
    Tacket CO; Sztein MB; Wasserman SS; Losonsky G; Kotloff KL; Wyant TL; Nataro JP; Edelman R; Perry J; Bedford P; Brown D; Chatfield S; Dougan G; Levine MM
    Infect Immun; 2000 Mar; 68(3):1196-201. PubMed ID: 10678926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans.
    Tacket CO; Sztein MB; Losonsky GA; Wasserman SS; Nataro JP; Edelman R; Pickard D; Dougan G; Chatfield SN; Levine MM
    Infect Immun; 1997 Feb; 65(2):452-6. PubMed ID: 9009296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant induction of CD4+ and CD8+ T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA.
    Salerno-Gonçalves R; Wyant TL; Pasetti MF; Fernandez-Viña M; Tacket CO; Levine MM; Sztein MB
    J Immunol; 2003 Mar; 170(5):2734-41. PubMed ID: 12594304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors.
    Levine MM; Galen J; Barry E; Noriega F; Chatfield S; Sztein M; Dougan G; Tacket C
    J Biotechnol; 1996 Jan; 44(1-3):193-6. PubMed ID: 8717403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C.
    Tacket CO; Galen J; Sztein MB; Losonsky G; Wyant TL; Nataro J; Wasserman SS; Edelman R; Chatfield S; Dougan G; Levine MM
    Clin Immunol; 2000 Nov; 97(2):146-53. PubMed ID: 11027455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors.
    Pickett TE; Pasetti MF; Galen JE; Sztein MB; Levine MM
    Infect Immun; 2000 Jan; 68(1):205-13. PubMed ID: 10603389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system.
    Tacket CO; Kelly SM; Schödel F; Losonsky G; Nataro JP; Edelman R; Levine MM; Curtiss R
    Infect Immun; 1997 Aug; 65(8):3381-5. PubMed ID: 9234801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.
    Wang JY; Noriega FR; Galen JE; Barry E; Levine MM
    Infect Immun; 2000 Aug; 68(8):4647-52. PubMed ID: 10899868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vi Capsular Polysaccharide Produced by Recombinant
    Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
    Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B.
    Wahid R; Zafar SJ; McArthur MA; Pasetti MF; Levine MM; Sztein MB
    Clin Vaccine Immunol; 2014 Mar; 21(3):427-34. PubMed ID: 24429069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.
    Wang JY; Pasetti MF; Noriega FR; Anderson RJ; Wasserman SS; Galen JE; Sztein MB; Levine MM
    Infect Immun; 2001 Aug; 69(8):4734-41. PubMed ID: 11447145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA.
    Frey SE; Lottenbach KR; Hill H; Blevins TP; Yu Y; Zhang Y; Brenneman KE; Kelly-Aehle SM; McDonald C; Jansen A; Curtiss R
    Vaccine; 2013 Oct; 31(42):4874-80. PubMed ID: 23916987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori infection affects immune responses following vaccination of typhoid-naive U.S. adults with attenuated Salmonella typhi oral vaccine CVD 908-htrA.
    Muhsen K; Pasetti MF; Reymann MK; Graham DY; Levine MM
    J Infect Dis; 2014 May; 209(9):1452-8. PubMed ID: 24273182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers.
    Metzger WG; Mansouri E; Kronawitter M; Diescher S; Soerensen M; Hurwitz R; Bumann D; Aebischer T; Von Specht BU; Meyer TF
    Vaccine; 2004 Jun; 22(17-18):2273-7. PubMed ID: 15149786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity.
    Dilts DA; Riesenfeld-Orn I; Fulginiti JP; Ekwall E; Granert C; Nonenmacher J; Brey RN; Cryz SJ; Karlsson K; Bergman K; Thompson T; Hu B; Brückner AH; Lindberg AA
    Vaccine; 2000 Feb; 18(15):1473-84. PubMed ID: 10618545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy.
    Chinchilla M; Pasetti MF; Medina-Moreno S; Wang JY; Gomez-Duarte OG; Stout R; Levine MM; Galen JE
    Infect Immun; 2007 Aug; 75(8):3769-79. PubMed ID: 17502396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children.
    Tran TH; Nguyen TD; Nguyen TT; Ninh TT; Tran NB; Nguyen VM; Tran TT; Cao TT; Pham VM; Nguyen TC; Tran TD; Pham VT; To SD; Campbell JI; Stockwell E; Schultsz C; Simmons CP; Glover C; Lam W; Marques F; May JP; Upton A; Budhram R; Dougan G; Farrar J; Nguyen VV; Dolecek C
    PLoS One; 2010 Jul; 5(7):e11778. PubMed ID: 20668668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.
    Kirkpatrick BD; McKenzie R; O'Neill JP; Larsson CJ; Bourgeois AL; Shimko J; Bentley M; Makin J; Chatfield S; Hindle Z; Fidler C; Robinson BE; Ventrone CH; Bansal N; Carpenter CM; Kutzko D; Hamlet S; LaPointe C; Taylor DN
    Vaccine; 2006 Jan; 24(2):116-23. PubMed ID: 16140433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
    Tacket CO; Hone DM; Losonsky GA; Guers L; Edelman R; Levine MM
    Vaccine; 1992; 10(7):443-6. PubMed ID: 1609547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine.
    Hone DM; Tacket CO; Harris AM; Kay B; Losonsky G; Levine MM
    J Clin Invest; 1992 Aug; 90(2):412-20. PubMed ID: 1644914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.